icad (ICAD)
icad Market Cap: 27.51M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ICAD Market Cap Rankings
| Overall | 8th percentile | 4271 of 4650 |
| Sector | 9th percentile | 783 of 865 in Technology |
| Industry | 5th percentile | 19 of 20 in Technical & System Software |
ICAD Market Cap Range, Past 5 Years
| Minimum | 25.70M | Sep 2011 |
| Maximum | 155.13M | Jun 2007 |
| Average | 73.60M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these ICAD related companies
ICAD News
$ICAD bought more today @ around .50 cents a share I feel this is a good buy. in 6-12 months i look for the price of this to double.
about 6 hours ago by miestro
about 6 hours ago by miestro
iCAD Announces First European Patients Treated with Xoft Radiation Therapy System
May 10, 12:45PM Benzinga
May 10, 12:45PM Benzinga
REVIEWING THE "I's:" Nice print last week @ L: $IFON & stock's ripped. L: $ICAD print shows mgmt executing but needed better from L: $IPAS.
about 22 days ago by Legacy_Trades
about 22 days ago by Legacy_Trades
Breastlink Medical Group to Offer iCAD’s Xoft Radiation Therapy System to Breast Cancer Patients
May 04, 9:30AM Business Wire
May 04, 9:30AM Business Wire
iCAD to Host First Quarter 2012 Financial Results Conference Call on Tuesday, May 8, 2012
Apr 30, 8:30AM Business Wire
Apr 30, 8:30AM Business Wire
iCAD Launches Post-Market Study of Intra-Operative Radiation Therapy to Treat Early Stage Breast Cancer
Mar 15, 10:00AM Business Wire
Mar 15, 10:00AM Business Wire
iCAD to Host Fourth Quarter 2011 Financial Results Conference Call on Tuesday, February 28, 2012
Feb 21, 6:00PM Business Wire
Feb 21, 6:00PM Business Wire
iCAD Announces Distribution Agreement with Carestream for MR Image Analysis and Mammography CAD
Dec 12, 2:15PM Benzinga
Dec 12, 2:15PM Benzinga
iCAD Showcases Its Computer-Aided Detection and Advanced Image Analysis Solutions at RSNA 2011
Nov 28, 11:09AM Business Wire
Nov 28, 11:09AM Business Wire
hft alert detects big algo activity in ICAD...penny stock hell i guess..$spy $ICAD http://chart.ly/2jrods8
about 190 days ago by HFTAlert
about 190 days ago by HFTAlert
iCAD Announces Recent Adoption of Its Xoft Electronic Brachytherapy System by Leading U. S. Hospitals
Nov 09, 9:43AM Business Wire
Nov 09, 9:43AM Business Wire
Icad, Inc. (ICAD) Posts Narrower than Expected Q3 Loss; Affirms Outlook
Oct 26, 4:50PM Street Insider
Oct 26, 4:50PM Street Insider
$ICAD The price action indicates a troubled stock, however is oversold and could rally. $S has better price action & is much more bullish
about 440 days ago by Spaniard
about 440 days ago by Spaniard
Does anyone have any insight on $icad Everything I read says it's great but the stock says NO?
about 440 days ago by bcarter674
about 440 days ago by bcarter674
iCAD $ICAD to Acquire Xoft for 8.47M Shares, $1M in Cash; Deal Valued at $13.1M
about 530 days ago by Street_Insider
about 530 days ago by Street_Insider
RT @Street_Insider: Icad $ICAD trading halted with news pending
about 530 days ago by aspenheights100
about 530 days ago by aspenheights100
@PaulWeinacht $ICAD FDA approval was not a big deal at the time is the problem.
about 580 days ago by johnwelshtrades
about 580 days ago by johnwelshtrades
@JohnWelshTrades You follow bios pretty closely...have you heard why $ICAD has been beat to hell since FDA approval?
about 580 days ago by paulweinacht
about 580 days ago by paulweinacht
@adamfeuerstein Any expectation on $ICAD? Down huge since FDA approval.
about 620 days ago by paulweinacht
about 620 days ago by paulweinacht
Watching $ICAD present now at Canaccord. Like the story - strong technology, good partners, lot of cancer to diagnose sadly #yam
about 659 days ago by Heuristocrat
about 659 days ago by Heuristocrat
Tough day for $ICAD with profit takers. Will add more if it falls under $2
about 663 days ago by paulweinacht
about 663 days ago by paulweinacht
Stock Breakout Aug 4th: 29 breakouts: $CPSL, $ICAD, $LAZ, $ONCY, $OPEN (stop: $43.49), $OEH (base + 200-day MA).. http://bit.ly/bBRw7Z
about 664 days ago by Fallond_Picks
about 664 days ago by Fallond_Picks
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ICAD | 0.51 | +0.03 | +6.01% | 25.95M |
| ICA | 6.22 | +0.19 | +3.15% | 930.37M |
| IBOC | 18.67 | +0.17 | +0.92% | 1.245B |
| IBN | 30.14 | +0.85 | +2.92% | 16.88B |
| IBM | 196.55 | +2.25 | +1.16% | 225.13B |
| GTY | 16.26 | +0.05 | +0.31% | 541.25M |
| GTXI | 3.14 | +0.07 | +2.28% | 192.80M |
| GTU | 57.54 | -0.86 | -1.47% | |
| GTSI | 7.73 | -0.01 | -0.13% | 74.69M |
| GTS | 17.69 | -0.10 | -0.56% | 505.77M |